home > news > 2009 > july > pfizer study investigates simcyp simulator for prediction of clinical drug-drug interactions
Pfizer study investigates Simcyp Simulator for prediction of clinical drug-drug interactions
Date: 16 Jul 2009
A new paper published in the journal Drug Metabolism and Disposition validates the use of predictive models in the early investigation of clinical drug-drug interactions (DDIs).
The study, ‘Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data; predictions of compounds as precipitants of interaction’, was undertaken by Odette S. Fahmi and colleagues at Pfizer.
The group collected DDI data on thirty drugs from over fifty clinical studies with midazolam, a probe substrate for CYP3A4. In vitro data reflecting competitive inhibition, time-dependent inhibition and induction of CYP3A4 were collected from the scientific literature. Two models, including the Simcyp Simulator which incorporates inter-individual variability, were then used to predict in vivo DDI from the in vitro data.
The authors conclude that in vivo DDI for CYP3A4 can be successfully predicted from in vitro data even when multiple interaction phenomena occur simultaneously.
Please click here to link to the abstract and full text options.